JP2000502052A5 - - Google Patents

Download PDF

Info

Publication number
JP2000502052A5
JP2000502052A5 JP1997519395A JP51939597A JP2000502052A5 JP 2000502052 A5 JP2000502052 A5 JP 2000502052A5 JP 1997519395 A JP1997519395 A JP 1997519395A JP 51939597 A JP51939597 A JP 51939597A JP 2000502052 A5 JP2000502052 A5 JP 2000502052A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP1997519395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000502052A (ja
Filing date
Publication date
Priority claimed from DE19543649A external-priority patent/DE19543649C2/de
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Application filed filed Critical
Priority claimed from PCT/EP1996/005126 external-priority patent/WO1997019169A1/de
Publication of JP2000502052A publication Critical patent/JP2000502052A/ja
Publication of JP2000502052A5 publication Critical patent/JP2000502052A5/ja
Abandoned legal-status Critical Current

Links

JP9519395A 1995-11-23 1996-11-21 腫瘍ワクチン及びその製造方法 Abandoned JP2000502052A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19543649A DE19543649C2 (de) 1995-11-23 1995-11-23 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19543649.0 1995-11-23
DE19607044.9 1996-02-24
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
PCT/EP1996/005126 WO1997019169A1 (de) 1995-11-23 1996-11-21 Tumorvakzine und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
JP2000502052A JP2000502052A (ja) 2000-02-22
JP2000502052A5 true JP2000502052A5 (enExample) 2004-10-21

Family

ID=26020603

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9519395A Abandoned JP2000502052A (ja) 1995-11-23 1996-11-21 腫瘍ワクチン及びその製造方法

Country Status (24)

Country Link
US (1) US20020085997A1 (enExample)
EP (1) EP0866851A1 (enExample)
JP (1) JP2000502052A (enExample)
KR (1) KR19990067653A (enExample)
CN (1) CN1202931A (enExample)
AR (1) AR004341A1 (enExample)
AU (1) AU720131B2 (enExample)
BG (1) BG62999B1 (enExample)
BR (1) BR9611466A (enExample)
CA (1) CA2238176A1 (enExample)
CO (1) CO4520254A1 (enExample)
CZ (1) CZ158998A3 (enExample)
EE (1) EE03778B1 (enExample)
HU (1) HUP0000318A3 (enExample)
NO (1) NO982329D0 (enExample)
NZ (1) NZ322910A (enExample)
PL (1) PL188537B1 (enExample)
RO (1) RO115275B1 (enExample)
RU (1) RU2206329C2 (enExample)
SK (1) SK66998A3 (enExample)
TR (1) TR199800912T2 (enExample)
TW (1) TW514530B (enExample)
UY (2) UY24367A1 (enExample)
WO (1) WO1997019169A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
DE69839273T2 (de) 1997-01-31 2009-03-05 Edward P. Chicago Cohen Krebsimmuntherapie mit semi-allogenen zellen
DE69731950T2 (de) * 1997-08-22 2005-05-19 Science Park Raf S.P.A. Tumorvakzinierung mittels Verwendung autologer oder HLA-verwandter Antigen präsentierender Zellen (APC), die mit einem Tumorantigen sowie einem eine Immunantwort hervorrufenden Fremdantigen transduziert sind
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
WO1999047687A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Enhanced anti-tumor immunity
FR2807661A1 (fr) * 2000-04-14 2001-10-19 Univ Nantes Agent et procede pour la simulation de lymphocytes t specifiques et lymphocytes t obtenus
EP1473564A4 (en) * 2001-09-18 2008-12-10 Greenpeptide Co Ltd METHOD FOR DETECTING CELL IMMUNITY AND ITS APPLICATION TO MEDICAMENTS
RU2203683C1 (ru) * 2001-09-20 2003-05-10 НИИ онкологии им. проф. Н.Н. Петрова Способ иммунотерапии костно-мозговыми дендритными клетками больных солидными опухолями
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
CN1871025B (zh) * 2003-08-25 2013-06-05 杨启明 基于印记位点调节物兄弟(boris)的预防性癌症疫苗
RU2267326C2 (ru) * 2004-03-16 2006-01-10 ГУН НИИ онкологии им. проф. Н.Н. Петрова Минздрава РФ Способ иммунотерапии опухолевым лизатом с адъювантом беталейкин больных солидными опухолями
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
NZ590431A (en) * 2005-02-23 2012-08-31 Genentech Inc Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
WO2006105255A2 (en) 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
ATE461215T1 (de) * 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
MX364370B (es) * 2012-07-12 2019-04-24 Persimmune Inc Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
JP6710004B2 (ja) 2016-03-15 2020-06-17 Repertoire Genesis株式会社 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
CA3187258A1 (en) 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes
JP2024511950A (ja) * 2021-03-12 2024-03-18 ティー-キュア バイオサイエンス,インコーポレイテッド Tcr-t療法に対する腫瘍細胞の感受性を広げるための腫瘍におけるhlaハプロタイプ発現の多様性の増強方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
EP0569678A3 (de) * 1992-03-13 1994-10-26 Yeda Res & Dev Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen.

Similar Documents

Publication Publication Date Title
JP2000500445A5 (enExample)
JP2000500228A5 (enExample)
JP2000500440A5 (enExample)
JPH11509113A5 (enExample)
JP2000500327A5 (enExample)
JPH11508770A5 (enExample)
JP2000500145A5 (enExample)
JP2000500155A5 (enExample)
JP2000500406A5 (enExample)
JP2000500361A5 (enExample)
JP2000500115A5 (enExample)
JP2000500322A5 (enExample)
JP2000500258A5 (enExample)
JP2000500342A5 (enExample)
JP2000500192A5 (enExample)
JP2000500112A5 (enExample)
JPH11508927A5 (enExample)
JPH11510314A5 (enExample)
JP2000500226A5 (enExample)
JP2000500397A5 (enExample)
JPH10512148A5 (enExample)
JP2000500407A5 (enExample)
JPH11508651A5 (enExample)
JP2000500166A5 (enExample)
JP2000500125A5 (enExample)